Delisting risk
Inovio Pharmaceuticals
Develops DNA medicines and CELLECTRA devices, led by INO-3107 for recurrent respiratory papillomatosis.
$1.29
After-hours close0.00 (0.00%)
At close$1.29(+2.38%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 49.43%34.16M sharesInsiders 0.56%389.8K sharesOther 50.01%34.55M shares
Shares outstanding 69.09M · Float —
Institutions13F, as of Jun 30, 2026
112 holders · 34.16M shares · 26 new positions · 55 increased · 16 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 8.45M | 12.24% | −884.8K | Aug 13, 2026 |
| Jupiter Topco LLC | 5.17M | 7.48% | +5.17Mnew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.65M | 5.28% | +749.4K | Aug 13, 2026 |
| Boxer Capital Management, LLC | 2.84M | 4.12% | +474.9K | Aug 14, 2026 |
| Adar1 Capital Management, LLC | 2.14M | 3.10% | +673.8K | Aug 14, 2026 |
| D. E. Shaw & Co., Inc. | 1.35M | 1.96% | −861.2K | Aug 14, 2026 |
| Stonepine Capital Management, LLC | 1.35M | 1.95% | +1.35Mnew | Aug 14, 2026 |
| Two Sigma Investments, LP | 1.24M | 1.79% | +849.4K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 13.50% | 9.34M | 13G | May 6, 2026 ↗ |
| Janus Henderson Group PLC | 9.99% | 6.67M | 13G | Dec 8, 2025 ↗ |
| RA Capital Management, L.P. | 9.90% | 10.67M | 13G | Aug 7, 2026 ↗ |
| Highbridge Capital Management LLC | 8.20% | 6.19M | 13G | May 15, 2026 ↗ |
| Alyeska Investment Group, L.P. | 5.99% | 4.00M | 13G | Feb 17, 2026 ↗ |
| Adage Capital Management, L.P. | 5.84% | 4.23M | 13G | May 13, 2026 ↗ |
| Vanguard Capital Management | 5.05% | 4.16M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jacqueline Elizabeth Shea | director, officer: Chief Executive Officer | 111.0K | 0.16% | May 21, 2026 |
| David B. Weiner | director | 87.6K | 0.13% | Feb 27, 2026 |
| Laurent Humeau | officer: Chief Scientific Officer | 46.8K | 0.07% | May 21, 2026 |
| Peter Kies | officer: CFO | 42.9K | 0.06% | May 21, 2026 |
| Michael John Sumner | officer: Chief Medical Officer | 42.0K | 0.06% | May 21, 2026 |
| Simon X. Benito | director | 12.2K | 0.02% | May 21, 2025 |
| Wendy L. Yarno | director | 10.5K | 0.02% | May 21, 2025 |
| Ann Calby Miller | director | 9.9K | 0.01% | May 21, 2025 |
| Jay Shepard | director | 9.2K | 0.01% | May 21, 2025 |
| Roger D. Dansey | director | 8.9K | 0.01% | May 21, 2025 |
1 ten-percent owner holds 81.7K shares by Form 4, outside the officers-and-directors figure above · 25 people have not refiled in the last 18 months (223.8K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.